Home/Pipeline/HSF1 Modulator Program

HSF1 Modulator Program

Infectious Diseases

Pre-clinicalActive

Key Facts

Indication

Infectious Diseases

Phase

Pre-clinical

Status

Active

Company

Sisu Pharma

About Sisu Pharma

Sisu Pharma is a private, preclinical-stage biotech founded in 2018 and based in San Diego, California. The company is pioneering a novel therapeutic strategy by directly targeting the transcription factor HSF1, a historically 'undruggable' master regulator of cellular stress protection. Its proprietary HI-LiTe platform enables the discovery of compounds that can either degrade or activate HSF1, with applications in oncology, neurodegeneration, and infection. Led by a team of seasoned scientists and drug developers, Sisu is advancing first-in-class compounds that have shown exceptional efficacy in resistant cancer models.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases Infectious Diseases

Other Infectious Diseases Drugs

Drug	Company	Phase	Status
inPROBE Platform	SDS Optic	Early R&D	Active
Potential Human POC Diagnostics	MatMaCorp	Research	Active
Nanoparticle Vaccines	Opko Health	Research	Active
Platform Vaccine Applications	Chimeron Bio	Discovery	Research
FMN riboswitch modulator	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Pre-Clinical	Exploratory
Ramoplanin™	Nanopharmaceutics	Clinical	Active
NanoDOX™	Nanopharmaceutics	Clinical	Active
Infectious Diseases	Menarini	Clinical	Active
Undisclosed Infectious Disease Program(s)	ATB therapeutics	Pre-clinical	Active
Vaccines for Infectious Diseases (undisclosed)	Takis	Pre-clinical	Active
Infectious Disease Diagnostics Program	Aptus Biosciences	Discovery	Active